JP5868521B2 - Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 - Google Patents

Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 Download PDF

Info

Publication number
JP5868521B2
JP5868521B2 JP2014549294A JP2014549294A JP5868521B2 JP 5868521 B2 JP5868521 B2 JP 5868521B2 JP 2014549294 A JP2014549294 A JP 2014549294A JP 2014549294 A JP2014549294 A JP 2014549294A JP 5868521 B2 JP5868521 B2 JP 5868521B2
Authority
JP
Japan
Prior art keywords
heterocyclyl
aryl
heteroaryl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014549294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506353A (ja
Inventor
チャンユー チョウ
チャンユー チョウ
シャオフイ ワン
シャオフイ ワン
クオリャン チャン
クオリャン チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of JP2015506353A publication Critical patent/JP2015506353A/ja
Application granted granted Critical
Publication of JP5868521B2 publication Critical patent/JP5868521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type
JP2014549294A 2011-12-31 2011-12-31 Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 Active JP5868521B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085146 WO2013097224A1 (en) 2011-12-31 2011-12-31 Fused tricyclic compounds as raf kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000312A Division JP6175519B2 (ja) 2016-01-04 2016-01-04 Ｒａｆキナーゼ阻害剤としての縮合三環式化合物

Publications (2)

Publication Number Publication Date
JP2015506353A JP2015506353A (ja) 2015-03-02
JP5868521B2 true JP5868521B2 (ja) 2016-02-24

Family

ID=48696279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549294A Active JP5868521B2 (ja) 2011-12-31 2011-12-31 Ｒａｆキナーゼ阻害剤としての縮合三環式化合物

Country Status (29)

Country Link
US (3) US9273046B2 (US07846941-20101207-C00154.png)
EP (2) EP2797888B1 (US07846941-20101207-C00154.png)
JP (1) JP5868521B2 (US07846941-20101207-C00154.png)
KR (1) KR101713391B1 (US07846941-20101207-C00154.png)
CN (1) CN103596926B (US07846941-20101207-C00154.png)
AU (1) AU2011384857B2 (US07846941-20101207-C00154.png)
BR (1) BR112014013108B1 (US07846941-20101207-C00154.png)
CA (1) CA2856347C (US07846941-20101207-C00154.png)
CY (1) CY1118226T1 (US07846941-20101207-C00154.png)
DK (1) DK2797888T3 (US07846941-20101207-C00154.png)
EA (1) EA025597B1 (US07846941-20101207-C00154.png)
ES (1) ES2588775T3 (US07846941-20101207-C00154.png)
HK (2) HK1192232A1 (US07846941-20101207-C00154.png)
HR (1) HRP20160641T1 (US07846941-20101207-C00154.png)
HU (1) HUE029656T2 (US07846941-20101207-C00154.png)
IL (1) IL233364A (US07846941-20101207-C00154.png)
IN (1) IN2014DN06166A (US07846941-20101207-C00154.png)
LT (1) LT2797888T (US07846941-20101207-C00154.png)
ME (1) ME02529B (US07846941-20101207-C00154.png)
MX (1) MX352617B (US07846941-20101207-C00154.png)
NZ (1) NZ624068A (US07846941-20101207-C00154.png)
PL (1) PL2797888T3 (US07846941-20101207-C00154.png)
PT (1) PT2797888T (US07846941-20101207-C00154.png)
RS (1) RS55196B1 (US07846941-20101207-C00154.png)
SG (1) SG11201401725SA (US07846941-20101207-C00154.png)
SI (1) SI2797888T1 (US07846941-20101207-C00154.png)
SM (1) SMT201600302B (US07846941-20101207-C00154.png)
WO (1) WO2013097224A1 (US07846941-20101207-C00154.png)
ZA (1) ZA201405555B (US07846941-20101207-C00154.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523270A (ja) * 2013-06-28 2016-08-08 ベイジーン リミテッド 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
JP2016523269A (ja) * 2013-06-28 2016-08-08 ベイジーン リミテッド Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物
JP2016196446A (ja) * 2016-01-04 2016-11-24 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ624068A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tricyclic compounds as raf kinase inhibitors
WO2015089809A1 (en) * 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015176267A1 (en) * 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beigene, Ltd. Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
EP3689868B1 (en) 2016-12-01 2023-09-27 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR102564201B1 (ko) * 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
IL300113A (en) 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Compressed cyclic RAF inhibitors and methods of using them
WO2023049060A1 (en) * 2021-09-21 2023-03-30 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
CN101087787A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 苯甲酰胺衍生物，它们的制备及作为药剂的应用
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1885723A2 (en) 2005-05-17 2008-02-13 Plexxikon, Inc. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
MX2007014510A (es) 2005-05-20 2008-02-05 Array Biopharma Inc Compuestos inhibidores de raf y metodos de uso de los mismos.
RS52010B (en) 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
KR20080052630A (ko) 2005-09-01 2008-06-11 어레이 바이오파마 인크. Ｒａｆ 억제제 화합물 및 그의 사용 방법
BRPI0619514A2 (pt) * 2005-12-08 2011-10-04 Millennium Pharm Inc compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos
JP5271895B2 (ja) * 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病性の二環式化合物
ES2373587T3 (es) * 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
CN101511828A (zh) 2006-09-06 2009-08-19 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的杂芳基衍生物
EP2061761A1 (en) 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
BRPI0811517A2 (pt) * 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase.
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
NZ624068A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tricyclic compounds as raf kinase inhibitors
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beigene, Ltd. Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523270A (ja) * 2013-06-28 2016-08-08 ベイジーン リミテッド 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
JP2016523269A (ja) * 2013-06-28 2016-08-08 ベイジーン リミテッド Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物
JP2016196446A (ja) * 2016-01-04 2016-11-24 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Also Published As

Publication number Publication date
KR20140108541A (ko) 2014-09-11
US10576087B2 (en) 2020-03-03
US20160206621A1 (en) 2016-07-21
US9273046B2 (en) 2016-03-01
HRP20160641T1 (hr) 2016-09-23
IL233364A (en) 2017-06-29
SMT201600302B (it) 2016-11-10
CN103596926B (zh) 2015-11-25
IL233364A0 (en) 2014-08-31
NZ624068A (en) 2016-09-30
CN103596926A (zh) 2014-02-19
US20190000857A1 (en) 2019-01-03
LT2797888T (lt) 2016-10-10
WO2013097224A1 (en) 2013-07-04
BR112014013108A2 (pt) 2017-06-13
EP2797888A1 (en) 2014-11-05
US9895376B2 (en) 2018-02-20
RS55196B1 (sr) 2017-01-31
EA201491305A1 (ru) 2015-04-30
SG11201401725SA (en) 2014-09-26
MX352617B (es) 2017-12-01
HK1221222A1 (zh) 2017-05-26
DK2797888T3 (en) 2016-09-19
CA2856347A1 (en) 2013-07-04
CY1118226T1 (el) 2017-06-28
KR101713391B1 (ko) 2017-03-07
SI2797888T1 (sl) 2017-01-31
JP2015506353A (ja) 2015-03-02
EP2797888B1 (en) 2016-06-08
US20150045355A1 (en) 2015-02-12
EA025597B1 (ru) 2017-01-30
AU2011384857B2 (en) 2016-03-03
EP3124472A1 (en) 2017-02-01
MX2014007829A (es) 2014-08-01
CA2856347C (en) 2017-05-30
HUE029656T2 (en) 2017-03-28
AU2011384857A1 (en) 2014-05-29
PL2797888T3 (pl) 2016-12-30
PT2797888T (pt) 2016-09-09
IN2014DN06166A (US07846941-20101207-C00154.png) 2015-08-21
HK1192232A1 (zh) 2014-08-15
BR112014013108B1 (pt) 2020-11-24
EP3124472B1 (en) 2018-07-25
EP2797888A4 (en) 2015-09-02
ES2588775T3 (es) 2016-11-04
ME02529B (me) 2017-02-20
ZA201405555B (en) 2015-10-28

Similar Documents

Publication Publication Date Title
JP5868521B2 (ja) Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP7207629B2 (ja) Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物
JP6380862B2 (ja) 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
EP3280715B1 (en) NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
JP6034877B2 (ja) Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
JP6175519B2 (ja) Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
TWI640518B (zh) 作爲ｒａｆ激酶抑制劑的稠合三環化合物
JP2017048214A (ja) Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN105348299A (zh) 作为raf激酶抑制剂的稠合三环化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160105

R150 Certificate of patent or registration of utility model

Ref document number: 5868521

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250